Introduction

The global crisis of antimicrobial resistance has created an urgent need for effective therapeutic options against multidrug-resistant bacterial pathogens. As newer antibiotics struggle to keep pace with evolving resistance mechanisms, physicians have turned their attention to previously discarded antimicrobial agents. Two such antibiotics, colistin and fosfomycin, have emerged from relative obscurity to become important tools in the fight against resistant infections.

Colistin, a polymyxin antibiotic discovered in 1949, was largely abandoned in the 1970s due to concerns about nephrotoxicity and neurotoxicity. Similarly, fosfomycin, discovered in 1969, saw limited use outside certain geographical regions despite its unique mechanism of action. The emergence of carbapenem-resistant bacteria and extensively drug-resistant organisms has prompted a reevaluation of these older agents.

This renewed interest has been accompanied by advances in understanding their pharmacokinetic properties, optimal dosing regimens, and appropriate clinical applications. Modern research has provided insights into how these antibiotics can be used more safely and effectively than in previous decades. The purpose of this paper is to examine the evidence supporting the clinical comeback of colistin and fosfomycin and to analyze their roles in contemporary antimicrobial therapy.

Historical Background and Development

Colistin Discovery and Early Use

Colistin belongs to the polymyxin family of antibiotics, specifically polymyxin E. Japanese researchers first isolated it from Bacillus polymyxa var. colistinus in 1949 (Koyama, 1950). The antibiotic gained widespread use in the 1950s and 1960s for treating gram-negative infections, particularly those caused by Pseudomonas species and Enterobacteriaceae.

During its early clinical years, colistin demonstrated remarkable activity against gram-negative bacteria. However, reports of severe nephrotoxicity and neurotoxicity began accumulating throughout the 1960s. These adverse effects, combined with the introduction of newer, seemingly safer antibiotics like aminoglycosides and beta-lactams, led to a dramatic decline in colistin use by the mid-1970s (Li et al., 2006).

Fosfomycin Origins

Fosfomycin was discovered in 1969 by scientists at Merck Research Laboratories, who isolated it from cultures of Streptomyces fradiae. The antibiotic’s unique phosphonic acid structure and novel mechanism of action distinguished it from other antimicrobial agents available at the time (Hendlin et al., 1969).

Despite its broad spectrum of activity and favorable safety profile, fosfomycin never achieved widespread adoption in many countries, including the United States. The antibiotic found more extensive use in Europe and Japan, where clinical experience accumulated over several decades. Limited availability and unfamiliarity among clinicians restricted its use in other regions.

The Resistance Crisis

The late 20th and early 21st centuries witnessed an alarming increase in antimicrobial resistance. The emergence of extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant organisms, and multidrug-resistant Acinetobacter baumannii created treatment challenges that existing antibiotics could not address adequately (Falagas & Kasiakou, 2005).

As physicians faced infections with limited treatment options, interest in older antibiotics began to resurface. Colistin, in particular, demonstrated retained activity against many of these resistant pathogens. Research groups began investigating ways to optimize its use while minimizing toxicity. Similarly, fosfomycin’s unique mechanism of action made it an attractive option for combination therapy against resistant organisms.

Pharmacological Properties

Colistin Mechanism of Action

Colistin exerts its antibacterial effect by disrupting bacterial cell membranes. The antibiotic acts as a cationic detergent, binding to lipopolysaccharides in the outer membrane of gram-negative bacteria. This interaction leads to membrane disruption, increased permeability, and ultimately bacterial cell death (Velkov et al., 2010).

The mechanism involves initial electrostatic attraction between the positively charged colistin molecule and negatively charged phosphate groups in bacterial lipopolysaccharides. This binding displaces divalent cations that normally stabilize the outer membrane, leading to destabilization and bacterial lysis.

Fosfomycin Mechanism of Action

Fosfomycin inhibits bacterial cell wall synthesis via a unique mechanism distinct from that of beta-lactam antibiotics. The drug acts as a phosphoenolpyruvate analog, irreversibly binding to UDP-N-acetylglucosamine enolpyruvyl transferase (MurA enzyme). This enzyme catalyzes the first committed step in peptidoglycan synthesis (Falagas et al., 2010).

The irreversible binding of fosfomycin to MurA provides sustained antibacterial activity. Additionally, the drug’s structural similarity to phosphoenolpyruvate allows it to utilize bacterial transport systems designed for this natural substrate, facilitating cellular uptake through both glucose-6-phosphate and glycerol-3-phosphate transport systems.

Pharmacokinetic Considerations

Colistin pharmacokinetics present unique challenges that have only recently been well characterized. The drug exists as an inactive prodrug (colistin methanesulfonate or CMS) when administered intravenously, which must be hydrolyzed to active colistin in vivo. This conversion process is slow and variable, leading to delayed onset of action and unpredictable plasma concentrations (Nation et al., 2017).

The distribution of colistin is limited by its large molecular size and charge properties. The drug penetrates poorly into most tissues, particularly the central nervous system. However, adequate concentrations can be achieved in lung tissue, making it suitable for respiratory tract infections.

Fosfomycin demonstrates more predictable pharmacokinetic behavior. The drug achieves good tissue penetration, including bone, prostate, and the central nervous system. Renal elimination accounts for most drug clearance, necessitating dose adjustments in patients with kidney dysfunction (Michalopoulos et al., 2011).

Clinical Applications and Efficacy

Colistin in Clinical Practice

Modern colistin use focuses primarily on infections caused by carbapenem-resistant gram-negative bacteria. Clinical studies have demonstrated efficacy in treating pneumonia, bloodstream infections, and urinary tract infections caused by multidrug-resistant Pseudomonas aeruginosa, Acinetobacter baumannii, and carbapenem-resistant Enterobacteriaceae (Dalfino et al., 2012).

Pneumonia represents one of the most common indications for colistin therapy. Studies comparing colistin-based regimens to other available treatments for ventilator-associated pneumonia caused by resistant organisms have shown comparable clinical outcomes. However, the quality of evidence remains limited due to the observational nature of many studies and the heterogeneity of patient populations.

Bloodstream infections caused by carbapenem-resistant organisms present particular challenges. While colistin demonstrates in vitro activity against these pathogens, clinical outcomes for bloodstream infections have been variable. Some studies suggest improved outcomes when colistin is used in combination with other active agents rather than as monotherapy (Falagas et al., 2010).

Fosfomycin Clinical Applications

Fosfomycin has found renewed interest for treating both complicated and uncomplicated infections. The drug’s activity against extended-spectrum beta-lactamase-producing organisms and some carbapenem-resistant bacteria makes it valuable for urinary tract infections and bone and joint infections, and for combination therapy in other resistant infections (Michalopoulos et al., 2012).

Uncomplicated cystitis represents the most well-established indication for fosfomycin. Single-dose oral therapy has proven effective for treating uncomplicated urinary tract infections, including those caused by extended-spectrum beta-lactamase-producing Escherichia coli. This application takes advantage of the drug’s excellent urinary concentrations and its favorable side-effect profile.

For more serious infections, intravenous fosfomycin has been used as part of combination therapy. Studies examining its use in osteomyelitis, particularly prosthetic joint infections, have shown promising results. The drug’s good bone penetration and activity against staphylococci make it particularly suitable for these applications.

Combination Therapy Strategies

Both colistin and fosfomycin are increasingly used in combination with other antibiotics to enhance efficacy and reduce the development of resistance. Synergy studies have identified several promising combinations that demonstrate enhanced activity against resistant pathogens.

Combinations of colistin with carbapenems, rifampin, or tigecycline have shown synergistic activity against Acinetobacter baumannii and Pseudomonas aeruginosa in laboratory studies. Clinical evidence supporting these combinations remains limited but suggests potential benefits for treating serious infections (Bergen et al., 2012).

Combinations of fosfomycin with beta-lactams, aminoglycosides, or fluoroquinolones have demonstrated enhanced activity against various Gram-positive and Gram-negative bacteria. The drug’s unique mechanism of action makes it an attractive combination partner, as resistance to fosfomycin typically does not confer cross-resistance to other antibiotic classes.

Resistance Patterns and Mechanisms

Colistin Resistance

Colistin resistance develops through modifications to bacterial lipopolysaccharides that reduce the drug’s binding affinity. The most well-characterized mechanism involves the addition of phosphoethanolamine or 4-amino-4-deoxy-L-arabinose to lipid A, reducing the negative charge of lipopolysaccharides and decreasing colistin binding (Olaitan et al., 2014).

Chromosomal mutations in genes such as pmrA, pmrB, phoP, phoQ, and mgrB can lead to constitutive expression of lipopolysaccharide modification enzymes. These mutations typically result in high-level colistin resistance that is stable even in the absence of selective pressure.

The discovery of plasmid-mediated colistin resistance genes (mcr genes) has raised particular concern. First identified in 2015, mcr-1 encodes a phosphoethanolamine transferase that can be horizontally transferred between bacteria. Subsequent discovery of additional mcr genes has highlighted the potential for rapid spread of colistin resistance (Liu et al., 2016).

Fosfomycin Resistance

Fosfomycin resistance can develop through multiple mechanisms, including reduced drug uptake, target modification, and enzymatic inactivation. Mutations affecting the glucose-6-phosphate and glycerol-3-phosphate transport systems can prevent fosfomycin from entering bacterial cells effectively (Castañeda-García et al., 2013).

Target site mutations in the murA gene can reduce fosfomycin’s binding affinity for UDP-N-acetylglucosamine enolpyruvyl transferase. However, such mutations often impose fitness costs on bacteria, potentially limiting their clinical relevance.

Enzymatic inactivation represents another resistance mechanism, particularly in gram-negative bacteria. Fosfomycin-modifying enzymes such as FosA, FosB, and FosX can inactivate the drug before it reaches its target. These enzymes are often encoded on mobile genetic elements, facilitating their spread between bacteria.

Table 1: Comparison of Colistin and Fosfomycin Resistance Mechanisms

Antibiotic	Primary Resistance Mechanisms	Genetic Basis	Clinical Impact
Colistin	LPS modification (phosphoethanolamine addition)	Chromosomal mutations (pmrA/B, phoP/Q, mgrB)	High-level resistance, stable
Colistin	LPS modification (plasmid-mediated)	mcr genes on mobile elements	Transferable resistance, moderate levels
Fosfomycin	Reduced uptake	Transport system mutations (uhpT, glpT)	Variable resistance levels
Fosfomycin	Target modification	murA gene mutations	Often associated with fitness costs
Fosfomycin	Enzymatic inactivation	Fosfomycin-modifying enzymes (FosA/B/X)	Variable, often plasmid-mediated

Safety Profiles and Adverse Effects

Colistin Toxicity

Nephrotoxicity remains the most concerning adverse effect associated with colistin use. Studies indicate that acute kidney injury occurs in approximately 30-60% of patients receiving intravenous colistin, with rates varying based on dosing regimens, patient populations, and definitions used for kidney injury (Hartzell et al., 2009).

The mechanism of colistin-induced nephrotoxicity involves direct tubular toxicity and potential vascular effects within the kidney. Risk factors for developing nephrotoxicity include advanced age, preexisting kidney disease, concurrent use of other nephrotoxic medications, and higher cumulative doses of colistin.

Modern dosing strategies based on pharmacokinetic modeling may help reduce nephrotoxicity risks while maintaining therapeutic efficacy. Loading doses followed by maintenance dosing adjusted for kidney function represent current best practices for minimizing adverse effects while achieving adequate drug exposure.

Neurotoxicity, while less common than nephrotoxicity, can manifest as paresthesias, dizziness, confusion, or, in severe cases, neuromuscular blockade. These effects are generally reversible upon drug discontinuation but may be more likely to occur in patients with kidney dysfunction due to drug accumulation.

Fosfomycin Safety Profile

Fosfomycin generally demonstrates a favorable safety profile compared to many other antibiotics. The most commonly reported adverse effects are gastrointestinal, including diarrhea, nausea, and abdominal discomfort. These effects are usually mild and resolve without intervention (Falagas et al., 2010).

The oral formulation of fosfomycin contains a notable amount of sodium, which may be problematic for patients with heart failure, hypertension, or other conditions requiring sodium restriction. Each 3-gram sachet contains approximately 2.1 grams of sodium, equivalent to about 5.4 grams of salt.

Intravenous fosfomycin has been associated with electrolyte disturbances, particularly hypokalemia and hyponatremia, likely related to the drug’s effects on renal tubular transport. Regular monitoring of electrolyte levels is recommended during prolonged intravenous therapy.

Central nervous system effects, including seizures, have been reported rarely with intravenous fosfomycin, particularly in patients with preexisting neurological conditions or when high doses are used. These effects appear to be dose-related and generally reversible.

Dosing Strategies and Optimization

Colistin Dosing Evolution

Traditional colistin dosing based on body weight has been largely replaced by more sophisticated approaches that account for the drug’s complex pharmacokinetics. The European Medicines Agency and other regulatory bodies have issued guidance recommending loading doses followed by maintenance dosing based on creatinine clearance (European Medicines Agency, 2014).

Current recommendations suggest loading doses of 6-9 million international units of colistin methanesulfonate (equivalent to approximately 240-360 mg of colistin base activity), followed by maintenance doses of 4.5-6 million international units every 12 hours, adjusted for kidney function. These dosing strategies aim to achieve target plasma concentrations while minimizing toxicity.

Therapeutic drug monitoring for colistin remains challenging due to analytical difficulties and the limited availability of assays. However, research suggests that maintaining steady-state plasma concentrations above 2 mg/L may be necessary for optimal clinical outcomes against most susceptible pathogens.

Fosfomycin Dosing Considerations

Fosfomycin dosing varies considerably based on the indication, route of administration, and severity of infection. For uncomplicated cystitis, a single 3-gram oral dose is typically sufficient and represents one of the simplest antibiotic regimens available.

For more serious infections requiring intravenous therapy, doses of 12-24 grams daily divided into three or four doses are commonly used. Higher doses may be necessary for infections caused by organisms with reduced susceptibility or for sites with poor drug penetration.

Dose adjustments are necessary in patients with kidney dysfunction, as fosfomycin is primarily eliminated through renal excretion. Recommended dose reductions range from 50% for moderate kidney impairment to 75% for severe impairment, with consideration for increasing dosing intervals.

Challenges and Limitations

Diagnostic and Susceptibility Testing Issues

Accurate susceptibility testing for both colistin and fosfomycin presents technical challenges that can impact clinical decision-making. Colistin susceptibility testing is notoriously difficult, with poor reproducibility between laboratories and methods. Broth microdilution remains the gold standard, but many clinical laboratories rely on less reliable methods (Clinical and Laboratory Standards Institute, 2020).

Fosfomycin susceptibility testing requires supplementation of the media with glucose-6-phosphate to support bacterial transport of the drug. Failure to use appropriate testing conditions can lead to falsely elevated minimum inhibitory concentrations and incorrect resistance determinations.

The lack of standardized breakpoints for some organism-antibiotic combinations further complicates the interpretation of susceptibility results. Clinicians must often rely on epidemiological cutoff values or expert recommendations rather than established clinical breakpoints.

Limited Clinical Evidence

Despite renewed interest in these older antibiotics, high-quality clinical evidence supporting their use remains limited. Most studies are observational, with inherent biases and confounding factors that limit the strength of their conclusions. Randomized controlled trials are difficult to conduct due to ethical considerations and the relatively uncommon nature of infections requiring these agents.

The heterogeneity of patient populations, infection sites, and causative organisms in published studies makes it challenging to develop evidence-based treatment guidelines. This limitation forces clinicians to rely on expert opinion and extrapolation from laboratory data when making treatment decisions.

Resistance Development Concerns

The increasing use of colistin and fosfomycin raises legitimate concerns about the development of resistance. Both antibiotics have relatively low genetic barriers to resistance, meaning that single mutations can sometimes confer clinically relevant levels of resistance.

The emergence and spread of plasmid-mediated colistin resistance (mcr genes) exemplifies these concerns. Since the initial discovery of mcr-1, additional mcr variants have been identified worldwide, suggesting ongoing evolution of resistance mechanisms.

Fosfomycin resistance can develop rapidly when the drug is used as monotherapy, particularly for the treatment of serious infections. This characteristic has led to recommendations for combination therapy in most clinical scenarios, but optimal combination partners and dosing strategies remain to be fully defined.

Modern Applications and Use Cases

Hospital-Acquired Infections

Both colistin and fosfomycin have found important roles in treating hospital-acquired infections caused by multidrug-resistant organisms. Ventilator-associated pneumonia represents a particularly challenging scenario where these agents may be life-saving options.

Colistin’s activity against carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii makes it a valuable treatment for respiratory tract infections in critically ill patients. Nebulized colistin may provide additional benefits by achieving high local concentrations in the lungs while potentially reducing systemic toxicity.

Fosfomycin’s broad spectrum of activity and good tissue penetration make it useful for various hospital-acquired infections, particularly when combined with other agents. Its activity against methicillin-resistant Staphylococcus aureus and some gram-negative bacteria provides therapeutic flexibility.

Urinary Tract Infections

Urinary tract infections represent one of the most successful applications for both antibiotics, particularly fosfomycin. The drug’s excellent urinary concentrations and single-dose oral regimen for uncomplicated cystitis provide distinct advantages over other available treatments.

Colistin can be useful for complicated urinary tract infections caused by carbapenem-resistant organisms, though its use should be reserved for cases where other options are not available due to toxicity concerns.

The increasing prevalence of extended-spectrum beta-lactamase-producing organisms causing urinary tract infections has made fosfomycin an increasingly valuable option, particularly in outpatient settings where oral therapy is preferred.

Prosthetic Joint Infections

Fosfomycin’s excellent bone penetration and activity against biofilm-forming bacteria have led to its use in the treatment of prosthetic joint infections. Combination therapy with rifampin or other agents active against staphylococci has shown promising results in small case series.

The drug’s ability to penetrate biofilms may provide advantages over other antibiotics in treating device-associated infections. However, the limited clinical evidence and potential for resistance development necessitate careful patient selection and monitoring.

Compassionate Use Scenarios

Both antibiotics serve important roles as salvage therapy for infections that have failed to respond to other treatments. In these compassionate use scenarios, the potential benefits may outweigh the risks of adverse effects, particularly for life-threatening infections.

A colleague recently shared an amusing anecdote about a patient who, upon hearing that his life-threatening infection would be treated with “an antibiotic from the 1940s,” asked whether the hospital had checked the expiration date. The patient’s concern, while understandable, highlighted the general lack of awareness about the renaissance of older antimicrobial agents. This interaction led to an educational opportunity about how sometimes the oldest tools can be the most effective against our newest microbial adversaries.

Comparative Analysis with Alternative Treatments

Comparison with Newer Antibiotics

Recent years have seen the introduction of several new antibiotics designed to address resistant gram-negative infections. Agents such as ceftazidime-avibactam, meropenem-vaborbactam, and cefiderocol offer alternatives to older antibiotics, such as colistin, for treating carbapenem-resistant infections.

These newer agents generally offer superior safety profiles compared to colistin, with lower rates of nephrotoxicity and other adverse effects. However, their spectra of activity may not cover all resistant organisms, and resistance development to these agents has already been reported in some regions.

Cost considerations also play a role in antibiotic selection, as newer agents are typically much more expensive than older antibiotics. Fosfomycin and colistin remain relatively inexpensive options, making them accessible in resource-limited settings where newer agents may not be available.

Combination Therapy vs. Monotherapy

The decision between monotherapy and combination therapy is a key point when using these older antibiotics. Combination therapy may offer benefits in terms of enhanced efficacy and reduced resistance development, but it also increases the risk of adverse effects and drug interactions.

For colistin, combination therapy is often preferred for serious infections, based on in vitro synergy data and observational clinical studies. Common combination partners include carbapenems, rifampin, and tigecycline, though optimal combinations remain to be definitively established.

Fosfomycin is almost always used in combination for serious infections because resistance develops rapidly when used as monotherapy. The drug’s unique mechanism of action makes it an attractive combination partner that may enhance the activity of other agents.

Role in Antimicrobial Stewardship

Both antibiotics play important roles in antimicrobial stewardship programs, serving as reserve agents for infections caused by highly resistant organisms. Their judicious use helps preserve the effectiveness of other antibiotics while providing treatment options for difficult infections.

Stewardship programs must balance the need to have these agents available for appropriate use while preventing overuse that could lead to resistance development. Preauthorization requirements and consultation with infectious disease specialists are common approaches used to ensure appropriate utilization.

Future Directions and Research Opportunities

Novel Formulations and Delivery Methods

Research into novel formulations and delivery methods may help overcome some of the limitations associated with these older antibiotics. Liposomal formulations of colistin are being investigated to reduce toxicity while maintaining efficacy. Early studies suggest that encapsulating colistin in liposomes may reduce nephrotoxicity while achieving adequate tissue concentrations.

Inhaled formulations of both antibiotics are being developed for the treatment of respiratory tract infections. These approaches may provide high local concentrations while minimizing systemic exposure and associated toxicity.

Sustained-release formulations could potentially improve dosing convenience and patient compliance while maintaining therapeutic drug levels. Such formulations may be particularly valuable for fosfomycin in the treatment of chronic or recurrent infections.

Pharmacokinetic and Pharmacodynamic Optimization

Continued research into the pharmacokinetic and pharmacodynamic properties of these antibiotics may lead to improved dosing strategies. Population pharmacokinetic modeling could help identify optimal dosing regimens for specific patient populations and infection types.

Therapeutic drug monitoring capabilities for both antibiotics need further development to enable personalized dosing approaches. Rapid, accurate assays suitable for routine clinical use could help optimize therapy while minimizing toxicity.

Understanding the pharmacodynamic drivers of efficacy for these agents could inform dosing strategies and combination approaches. Research into biomarkers that predict treatment response could help guide therapy selection and monitoring.

Resistance Prevention Strategies

Developing strategies to prevent or delay the development of resistance is a critical research priority. Understanding the fitness costs associated with resistance mutations may help predict the likelihood of resistance emergence and persistence.

Combination therapy strategies need further investigation to identify optimal partners and dosing approaches. Mathematical modeling could help predict the likelihood of resistance development with different combination regimens.

Novel approaches, such as resistance reversal agents or adjuvants that enhance antibiotic activity, may help extend the useful lifespan of these important agents.

Global Access and Implementation

Ensuring global access to these important antibiotics represents both a challenge and an opportunity. While both agents are relatively inexpensive, regulatory hurdles and a lack of commercial interest in some regions may limit availability.

Developing evidence-based treatment guidelines that can be adapted for different resource settings could help standardize the use of these agents while accounting for local epidemiology and available resources.

Educational initiatives to improve healthcare provider knowledge about these antibiotics could help ensure appropriate use and optimal outcomes when they are employed.

Regulatory Considerations and Guidelines

Regulatory Status and Approvals

The regulatory status of colistin and fosfomycin varies considerably between countries and regions. Colistin is available in most countries but may be marketed under different formulations or brand names. Regulatory agencies have issued guidance on dosing and safety monitoring, but recommendations may differ between jurisdictions.

Fosfomycin availability is more limited: the oral formulation is approved in many countries for treating uncomplicated urinary tract infections, while intravenous formulations may not be available in all regions. The United States approved intravenous fosfomycin in 2020, expanding treatment options for American physicians.

Regulatory agencies continue to evaluate the benefit-risk profiles of these agents as new evidence becomes available. Updated prescribing information and safety warnings reflect evolving understanding of optimal use and risk mitigation strategies.

Clinical Practice Guidelines

Professional medical societies and expert panels have begun incorporating these older antibiotics into clinical practice guidelines for treating resistant infections. The Infectious Diseases Society of America, European Society of Clinical Microbiology and Infectious Diseases, and other organizations have published recommendations for their use.

Guidelines generally recommend reserving these agents for infections caused by organisms with limited treatment options, emphasizing the importance of appropriate patient selection and monitoring. Combination therapy is often recommended for serious infections to enhance efficacy and reduce the development of resistance.

Antimicrobial stewardship guidelines increasingly address the appropriate use of these agents, providing frameworks to ensure judicious use while maintaining their availability for appropriate clinical scenarios.

Quality Assurance and Manufacturing

Quality control issues have occasionally affected the availability and reliability of these older antibiotics. Manufacturing challenges, such as complex production processes or limited commercial interest, can lead to supply disruptions.

Regulatory oversight of manufacturing quality has intensified as these agents have gained renewed clinical importance. Agencies have implemented additional requirements for quality testing and stability assessment to ensure consistent product quality.

Generic formulations of both antibiotics are available in many markets, but quality variations between manufacturers may affect clinical outcomes. Healthcare systems must carefully evaluate suppliers and implement quality assurance measures.

Economic Considerations

Cost-Effectiveness Analysis

The cost-effectiveness of older antibiotics such as colistin and fosfomycin compared to newer agents is an important consideration for healthcare systems. While these older agents are typically less expensive to acquire, their use may entail additional monitoring costs and potential adverse effects, thereby increasing overall treatment expenses.

Studies examining the economic impact of colistin use have found that while drug costs are relatively low, the need for intensive monitoring and management of adverse effects can increase total treatment costs. Nephrotoxicity may require renal replacement therapy or extended hospitalization, adding substantial costs to treatment.

Fosfomycin’s favorable safety profile may offer economic benefits by reducing monitoring requirements and minimizing adverse effects. The single-dose oral treatment for uncomplicated urinary tract infections offers particular cost advantages through improved patient compliance and reduced follow-up requirements.

Healthcare Resource Utilization

The use of these antibiotics in hospitalized patients may affect length of stay, intensive care unit utilization, and other healthcare resources. Effective treatment of resistant infections may reduce overall healthcare costs by preventing treatment failures and complications.

Conversely, adverse effects associated with these agents, particularly colistin’s nephrotoxicity, may increase resource utilization and costs. Healthcare systems must balance the immediate costs of treatment against the potential long-term benefits of successful infection control.

The role of these antibiotics in preventing healthcare-associated infection outbreaks may provide additional economic benefits that are difficult to quantify but potentially substantial.

Global Health Implications

In resource-limited settings, the relatively low cost of these older antibiotics may make them an important option for treating resistant infections when newer, more expensive agents are unavailable. However, limited laboratory infrastructure for susceptibility testing and therapeutic monitoring may complicate their optimal use.

The emergence of resistance to these agents could have particularly severe implications in settings where treatment options are already limited. International efforts to support appropriate use and resistance monitoring are essential to preserve their effectiveness globally.

Frequently Asked Questions

When should colistin be considered for treatment?

Colistin should be reserved for infections caused by multidrug-resistant gram-negative bacteria when other treatment options are limited or unavailable. Common indications include infections caused by carbapenem-resistant Pseudomonas aeruginosa, Acinetobacter baumannii, or Enterobacteriaceae. The decision to use colistin should involve infectious disease consultation when available, and patients should be closely monitored for nephrotoxicity and neurotoxicity.

Is fosfomycin effective for complicated urinary tract infections?

Fosfomycin can be effective for complicated urinary tract infections, particularly those caused by extended-spectrum beta-lactamase-producing organisms. However, treatment typically requires multiple doses rather than the single-dose regimen used for uncomplicated cystitis. Combination therapy with other active agents is often recommended to prevent the development of resistance and enhance efficacy.

How should patients be monitored while receiving colistin therapy?

Patients receiving colistin require regular monitoring of kidney function, including serum creatinine and blood urea nitrogen levels. Daily monitoring is recommended during the initial days of therapy, with the frequency adjusted based on clinical stability and risk factors. Electrolyte levels, particularly magnesium and potassium, should also be monitored. Neurological symptoms should be assessed regularly, and dose adjustments may be necessary based on changes in kidney function.

Can these antibiotics be used in pediatric patients?

Both colistin and fosfomycin can be used in pediatric patients, though data supporting their use in children are limited. Dosing adjustments based on age and weight are necessary, and close monitoring for adverse effects is essential. Pediatric use should generally be reserved for serious infections with limited treatment alternatives and should involve consultation with pediatric infectious disease specialists when available.

What are the most common drug interactions with fosfomycin?

Fosfomycin has relatively few drug interactions compared to many other antibiotics. The most clinically relevant interactions involve drugs that affect renal function, as fosfomycin is primarily eliminated through the kidneys. Metoclopramide may reduce oral fosfomycin absorption and should be avoided when possible. The high sodium content in oral fosfomycin preparations may be problematic for patients taking medications for heart failure or hypertension.

How long can treatment with these antibiotics be continued?

Treatment duration depends on the type and severity of infection, patient response, and tolerance of the medication. For uncomplicated urinary tract infections, single-dose fosfomycin may be sufficient. For serious infections, treatment courses of 7-14 days are common, though some infections may require longer therapy. Colistin treatment should be limited to the shortest duration necessary due to toxicity concerns, while fosfomycin may be used for longer periods if well tolerated.

Are there any contraindications to using these antibiotics?

Colistin is contraindicated in patients with known hypersensitivity to polymyxin antibiotics. Caution is advised in patients with preexisting kidney disease, neuromuscular disorders, or concurrent use of other nephrotoxic medications. Fosfomycin is contraindicated in patients with known hypersensitivity and should be used cautiously in patients with severe kidney impairment. The high sodium content in oral preparations may contraindicate their use in certain cardiac patients.

What is the role of therapeutic drug monitoring for these antibiotics?

Therapeutic drug monitoring for colistin is challenging due to analytical difficulties, but it may be beneficial in optimizing therapy while minimizing toxicity. Target plasma concentrations of 2-4 mg/L have been suggested, though clinical correlation with outcomes remains limited. Fosfomycin therapeutic drug monitoring is not routinely performed but may be considered in patients with altered pharmacokinetics or when treating infections caused by organisms with elevated minimum inhibitory concentrations.

References

Bergen, P. J., Landersdorfer, C. B., Zhang, J., Zhao, M., Lee, H. J., Nation, R. L., & Li, J. (2012). Pharmacokinetics and pharmacodynamics of ‘old’ polymyxins: What is new? Diagnostic Microbiology and Infectious Disease, 74(3), 213-223.

Castañeda-García, A., Rodríguez-Rojas, A., Guelfo, J. R., & Blázquez, J. (2013). The glycerol-3-phosphate permease GlpT is the only fosfomycin transporter in Pseudomonas aeruginosa. Journal of Bacteriology, 195(22), 6968-6974.

Clinical and Laboratory Standards Institute. (2020). Performance standards for antimicrobial susceptibility testing (30th ed.). CLSI supplement M100. Clinical and Laboratory Standards Institute.

Dalfino, L., Puntillo, F., Mosca, A., Monno, R., Spada, M. L., Coppolecchia, S., Miragliotta, G., & Bruno, F. (2012). High-dose, extended-interval colistin administration in critically ill patients: Is this the right dosing strategy? A preliminary study. Clinical Infectious Diseases, 54(12), 1720-1726.

European Medicines Agency. (2014). Revised EPAR summary for the public: Colistin. European Medicines Agency.

Falagas, M. E., & Kasiakou, S. K. (2005). Colistin: The revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clinical Infectious Diseases, 40(9), 1333-1341.

Falagas, M. E., Kastoris, A. C., Kapaskelis, A. M., & Karageorgopoulos, D. E. (2010). Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum β-lactamase-producing, Enterobacteriaceae infections: A systematic review. The Lancet Infectious Diseases, 10(1), 43-50.

Hartzell, J. D., Neff, R., Ake, J., Howard, R., Olson, S., Paolino, K., Vishnepolsky, M., Weintrob, A., & Wortmann, G. (2009). Nephrotoxicity associated with intravenous colistin (polymyxin E) therapy. Clinical Infectious Diseases, 48(12), 1724-1728.

Hendlin, D., Stapley, E. O., Jackson, M., Wallick, H., Miller, A. K., Wolf, F. J., Miller, T. W., Chaiet, L., Kahan, F. M., Foltz, E. L., Woodruff, H. B., Mata, J. M., Hernandez, S., & Mochales, S. (1969). Phosphonomycin, a new antibiotic produced by strains of Streptomyces. Science, 166(3901), 122-123.

Koyama, Y. (1950). A new antibiotic ‘colistin’ produced by spore-forming soil bacteria. Journal of Antibiotics, 3(8), 457-458.

Li, J., Nation, R. L., Turnidge, J. D., Milne, R. W., Coulthard, K., Rayner, C. R., & Paterson, D. L. (2006). Colistin: The re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections. The Lancet Infectious Diseases, 6(9), 589-601.

Liu, Y. Y., Wang, Y., Walsh, T. R., Yi, L. X., Zhang, R., Spencer, J., Doi, Y., Tian, G., Dong, B., Huang, X., Yu, L. F., Gu, D., Ren, H., Chen, X., Lv, L., He, D., Zhou, H., Liang, Z., Liu, J. H., & Shen, J. (2016). Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: A microbiological and molecular biological study. The Lancet Infectious Diseases, 16(2), 161-168.

Michalopoulos, A. S., Livaditis, I. G., & Gougoutas, V. (2011). The revival of fosfomycin. International Journal of Infectious Diseases, 15(11), e732-e739.

Michalopoulos, A. S., Tsiodras, S., Rellos, K., Mentzelopoulos, S., & Falagas, M. E. (2005). Colistin treatment in patients with ICU-acquired infections caused by multiresistant gram-negative bacteria: The renaissance of an old antibiotic. Clinical Microbiology and Infection, 11(2), 115-121.

Nation, R. L., Rigatto, M. H. P., Falci, D. R., & Zavascki, A. P. (2017). Polymyxin acute kidney injury: Dosing and other strategies to reduce toxicity. Antibiotics, 6(4), 24.

Olaitan, A. O., Morand, S., & Rolain, J. M. (2014). Mechanisms of polymyxin resistance: Acquired and intrinsic resistance in bacteria. Frontiers in Microbiology, 5, 643.

Velkov, T., Thompson, P. E., Nation, R. L., & Li, J. (2010). Structure-activity relationships of polymyxin antibiotics. Journal of Medicinal Chemistry, 53(5), 1898-1916.